Multilevel Resilience and Appointment Attendance Among African American/Black Adults with HIV: A Prospective Multisite Cohort Study

被引:0
作者
Wilson-Barthes, Marta G. [1 ]
Park, Jee Won [1 ,2 ]
Mugavero, Michael J. [3 ]
Napravnik, Sonia [4 ]
Carey, Michael P. [5 ]
Fava, Joseph L. [5 ]
Dale, Sannisha K. [6 ]
Earnshaw, Valerie A. [7 ]
Agil, Deana [4 ]
Howe, Chanelle J. [1 ]
Dulin, Akilah J. [8 ]
机构
[1] Brown Univ, Sch Publ Hlth, Dept Epidemiol, Ctr Epidemiol Res, 121 South Main St,Box G-S121-2, Providence, RI 02912 USA
[2] Univ Delaware, Program Epidemiol, Newark, DE USA
[3] Univ Alabama Birmingham, Dept Med, Div Infect Dis, Ctr AIDS Res, Birmingham, AL USA
[4] Univ North Carolina Chapel Hill, Gillings Sch Global Publ Hlth, Dept Med, Div Infect Dis,Sch Med,Dept Epidemiol, Chapel Hill, NC USA
[5] Brown Univ, Warren Alpert Med Sch, Miriam Hosp, Ctr Behav & Prevent Med,Dept Psychiat & Human Beha, Providence, RI USA
[6] Univ Miami, Dept Psychol, Coral Gables, FL USA
[7] Univ Delaware, Dept Human Dev & Family Sci, Newark, DE USA
[8] Brown Univ, Sch Publ Hlth, Ctr Hlth Promot & Hlth Equ, Dept Behav & Social Sci, Providence, RI USA
基金
美国国家卫生研究院;
关键词
Black; Clinic attendance; Clinical cohort; HIV; Neighborhood environment; Racial disparities; Resilience; Visit adherence; PARTIAL IDENTIFICATION; ADJUVANT CHEMOTHERAPY; STAGE-III; TRASTUZUMAB; IPILIMUMAB;
D O I
10.1097/EDE.0000000000001801
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background:Attending clinic appointments supports HIV viral suppression, yet racial disparities are documented. We assessed whether multilevel resilience resources were associated with appointment attendance among African American/Black (AA/B) adults living with HIV in the United States.Methods:We ascertained data from 291 AA/B clinical cohort participants from 2018 to 2021. We assessed resilience using the Multilevel Resilience Resource Measure. Binary outcomes were a nonrepeated indicator of attending >= 87.5% of scheduled HIV appointments over 12 months (i.e., visit adherence) and a repeated measure of attending appointments during two sequential 6-month follow-up windows (i.e., clinic attendance). Modified Poisson models estimated adjusted risk ratios (aRRs).Results:The aRR for clinic attendance among participants with greater versus lesser multilevel resilience resource endorsement was 0.95 (95% confidence interval: 0.88, 1.0). The aRR for visit adherence among participants with greater versus lesser multilevel resilience resource endorsement was 1.2 (0.95, 1.4).Conclusions:This analysis is one of the first to assess appointment attendance as a function of resilience. Findings should be confirmed in larger cohorts.
引用
收藏
页码:99 / 106
页数:8
相关论文
共 29 条
  • [11] Partial Identification of Personalized Treatment Response with Trial-reported Analyses of Binary Subgroups
    Li, Sheyu
    Litvin, Valentyn
    Manski, Charles F.
    [J]. EPIDEMIOLOGY, 2023, 34 (03) : 319 - 324
  • [12] Manski C. F., 2019, Patient Care under Uncertainty
  • [13] Monotone treatment response
    Manski, CF
    [J]. ECONOMETRICA, 1997, 65 (06) : 1311 - 1334
  • [14] Econometrics for Decision Making: Building Foundations Sketched by Haavelmo and Wald
    Manski, Charles F.
    [J]. ECONOMETRICA, 2021, 89 (06) : 2827 - 2853
  • [15] Statistical Decision Properties of Imprecise Trials Assessing Coronavirus Disease 2019 (COVID-19) Drugs
    Manski, Charles F.
    Tetenov, Aleksey
    [J]. VALUE IN HEALTH, 2021, 24 (05) : 641 - 647
  • [16] Bounding the Accuracy of Diagnostic Tests, With Application to COVID-19 Antibody Tests
    Manski, Charles F.
    [J]. EPIDEMIOLOGY, 2021, 32 (02) : 162 - 167
  • [17] Trial Size for Near-Optimal Choice Between Surveillance and Aggressive Treatment: Reconsidering MSLT-II
    Manski, Charles F.
    Tetenov, Aleksey
    [J]. AMERICAN STATISTICIAN, 2019, 73 : 305 - 311
  • [18] Reasonable patient care under uncertainty
    Manski, Charles F.
    [J]. HEALTH ECONOMICS, 2018, 27 (10) : 1397 - 1421
  • [19] THE 2009 LAWRENCE R. KLEIN LECTURE: DIVERSIFIED TREATMENT UNDER AMBIGUITY
    Manski, Charles F.
    [J]. INTERNATIONAL ECONOMIC REVIEW, 2009, 50 (04) : 1013 - 1041
  • [20] Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation
    Peer, Cody J.
    Heiss, Brian L.
    Goldstein, Daniel A.
    Goodell, Jennifer C.
    Figg, William D.
    Ratain, Mark J.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 62 (04) : 532 - 540